BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T, Otsuka F. Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol. 2018;11:549-556. [PMID: 30186138 DOI: 10.1159/000491862] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
2 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 2019;111:92-7. [PMID: 31748755 DOI: 10.32074/1591-951X-24-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-0752-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
5 Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43. [PMID: 32856210 DOI: 10.1007/s00520-020-05707-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
7 Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J 2019;6:e00249. [PMID: 32309466 DOI: 10.14309/crj.0000000000000249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ebisutani N, Tozawa K, Matsuda I, Nakamura K, Tamura A, Hara K, Kondo T, Terada T, Tomita T, Oshima T, Fukui H, Hirota S, Miwa H. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis. Dig Dis Sci 2021;66:2461-5. [PMID: 32780186 DOI: 10.1007/s10620-020-06529-3] [Reference Citation Analysis]
9 Omotehara S, Nishida M, Yamanashi K, Sakurai K, Katsurada T, Komatsu Y, Shimizu A, Shibuya H, Shinagawa N, Sugita J, Teshima T. A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography. J Clin Ultrasound 2021;49:605-9. [PMID: 33580597 DOI: 10.1002/jcu.22975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]